Combined use of oral estramustine phosphate and oral etoposide in patients with hormone refractory prostate carcinoma
- VernacularTitle:磷酸雌二醇氮芥联合足叶乙甙治疗激素抵抗性前列腺癌
- Author:
Zhongquan SUN
;
Weiqing QIAN
;
Jianda SONG
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Carcinoma;
Hormone refractory;
Estramustine phosphate;
Etoposide
- From:
Chinese Journal of Urology
2000;0(01):-
- CountryChina
- Language:Chinese
-
Abstract:
50% for more than 1 month as effective,and the efficacy for soft tissue metastases were classified as complete,partial remission,stabilization and progression.Results All patients were followed up for 6-24 months(mean,12 months) with the evaluation of efficacy and toxicity.PSA levels decreased by at least 50% in 6 of 12 cases(50%);it decreased from(63.9?47.3)ng/ml before treatment to(14.4?8.8)ng/ml after treatment,with a mean duration of response being 7.5 months(range,5-12 months).Partial remission of soft tissue metastases was obtained in 2 cases;the metastatic lesions were reduced from 4.0 cm?5.0 cm,(3.0cm?)(3.5) cm to 2.0 cm?2.0 cm,1.0 cm?1.5 cm,respectively,by the treatment,with response duration being 3 and 8 months,respectively.Toxicities were minimal with leukopenia at grade Ⅰ in 1 case,anemia at grade Ⅰ in 1,baldness at grade Ⅰ in 1,nausea at grade Ⅰ in 2 and impaired liver function at grade Ⅱ in 1.Conclusions The combination of oral estramustine phosphate and oral etoposide may be an effective and well-tolerated regimen in patients with HRPC.
